Second thoughts about safety of St. John's wort

Lancet

Volumn 354, Issue 9195, 1999, Pages 2014-2016

  Ernst, E ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOSPORIN; DESOGESTREL PLUS ETHINYLESTRADIOL; DIGOXIN; HYPERICUM EXTRACT; LIVER ENZYME; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; WARFARIN;

DEPRESSION; DIGOXIN BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERICUM PERFORATUM; MYALGIA; NOTE; PRIORITY JOURNAL; SEROTONIN SYNDROME; TREMOR;

EID: 0033547648     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00418-3     Document Type: Note

References (16)

1. Brevoort P. The booming US botanical market. HerbalGram. 44:1998;33-48.
2. Harrison P. Herbal medicine takes root in Germany. CMAJ. 158:1998;637-639.
3. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. St John's Wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 313:1996;253-258.
4. Müller W.E., Rolli M., Schäfer C., Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 30:1997;102-107. (suppl 2).
5. Stevinson C., Ernst E. Safety of Hypericum in patients with depression. CNS Drugs. 11:1999;125-132.
6. Nebel A., Schneider B.J., Baker R.K., Kroll D.J. Potential metabolic interaction between St. John's Wort and theophylline. Ann Pharmacother. 33:1999;502.
7. Rey J.M., Walter G. Hypericum perforatum (St John's Wort) in depression: pest or blessing? Med J Aust. 169:1998;583-586.
8. Bon S., Hartmann K., Kuhn M. Johanniskraut ein Enzyminduktor? Schweitzer Apothekerzeitung. 16:1999;535-536.
9. Roby CA, Kantor E, Anderson GD, Burstein AH. St John's Wort impact on CYP3A4 activity. Proceedings of the 39th Annual Meeting, New Clinical Drug Evaluation Unit, Boca Raton, FL: June, 1999 (poster 129).
10. Ereshefsky B, Gewertz N, Lam YWF, Vega LM, Ereshefsky L. Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. Proceedings of the 39th Annual Meeting, New Clinical Drug Evaluation Unit, Boca Raton, FL: June, 1999 (poster 130).
11. Gewertz N, Ereshefsky B, Lam YWF, Benavides R, Ereshefsky L. Determination of the differential effects of St. John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology. Proceedings of the 39th Annual Meeting, New Clinical Drug Evaluation Unit, Boca Raton, FL: June, 1999 (poster 131).
12. Maurer A., Johne A., Bauer S.et al. Interaction of St. John's wort extract with phenprocoumon. Eur J Clin Pharmacol. 55:1999;22. (abstr).
13. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Interaction of St. John's Wort extract with digoxin. Jahreskongress für Klinische Pharmakologie, Berlin, Juni 10-12, 1999.
14. Lantz M.S., Buchalter E., Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol. 12:1999;7-10.
15. Martin T.G. Serotonin syndrome. Ann Emerg Med. 28:1996;520-526.
16. Mastrangelo M.J., Bellet R.E., Berd D. Prognostic factors. Clark W.H., Goldman L.I., Mastrangelo J.M. Human malignant melanoma. 1979;1-113 Grune and Stratton, New York.